<!DOCTYPE html><html><head><title> Pacifica Code Section 26-61a-S104 </title><link rel="stylesheet" href="../../../assets/style.css"/></head><body>
<b><i>
                      Effective 3/24/2022</i></b>
<br>
<b>26-61a-104.&nbsp;
          </b><b>Qualifying condition.</b>
<br>
<a id="26-61a-104(1)" name="26-61a-104(1)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(1)</td><td style="width:99%">
By designating a particular condition under Subsection <a href="#26-61a-104(2)">(2)</a> for which the use of medical cannabis to treat symptoms is decriminalized, the Legislature does not conclusively state that:
<a id="26-61a-104(1)(a)" name="26-61a-104(1)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
current scientific evidence clearly supports the efficacy of a medical cannabis treatment for the condition; or</td>
</tr>
</tbody></table>
<a id="26-61a-104(1)(b)" name="26-61a-104(1)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
a medical cannabis treatment will treat, cure, or positively affect the condition.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)" name="26-61a-104(2)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(2)</td><td style="width:99%">
For the purposes of this chapter, each of the following conditions is a qualifying condition:
<a id="26-61a-104(2)(a)" name="26-61a-104(2)(a)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(a)</td><td style="width:99%">
HIV or acquired immune deficiency syndrome;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(b)" name="26-61a-104(2)(b)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(b)</td><td style="width:99%">
Alzheimer's disease;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(c)" name="26-61a-104(2)(c)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(c)</td><td style="width:99%">
amyotrophic lateral sclerosis;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(d)" name="26-61a-104(2)(d)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(d)</td><td style="width:99%">
cancer;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(e)" name="26-61a-104(2)(e)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(e)</td><td style="width:99%">
cachexia;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(f)" name="26-61a-104(2)(f)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(f)</td><td style="width:99%">
persistent nausea that is not significantly responsive to traditional treatment, except for nausea related to:<a id="26-61a-104(2)(f)(i)" name="26-61a-104(2)(f)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
pregnancy;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(f)(ii)" name="26-61a-104(2)(f)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
cannabis-induced cyclical vomiting syndrome; or</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(f)(iii)" name="26-61a-104(2)(f)(iii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(iii)</td><td style="width:99%">
cannabinoid hyperemesis syndrome;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(g)" name="26-61a-104(2)(g)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(g)</td><td style="width:99%">
Crohn's disease or ulcerative colitis;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(h)" name="26-61a-104(2)(h)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(h)</td><td style="width:99%">
epilepsy or debilitating seizures;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(i)" name="26-61a-104(2)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
multiple sclerosis or persistent and debilitating muscle spasms;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(j)" name="26-61a-104(2)(j)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(j)</td><td style="width:99%">
post-traumatic stress disorder that is being treated and monitored by a licensed mental health therapist, as that term is defined in Section <a href="../../Title58/Chapter60/58-60-S102.html?v=C58-60-S102_2021050520210505">58-60-102</a>, and that:<a id="26-61a-104(2)(j)(i)" name="26-61a-104(2)(j)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
has been diagnosed by a healthcare provider or mental health provider employed or contracted by the United States Veterans Administration, evidenced by copies of medical records from the United States Veterans Administration that are included as part of the qualified medical provider's pre-treatment assessment and medical record documentation; or</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(j)(ii)" name="26-61a-104(2)(j)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
has been diagnosed or confirmed, through face-to-face or telehealth evaluation of the patient, by a provider who is:
<a id="26-61a-104(2)(j)(ii)(A)" name="26-61a-104(2)(j)(ii)(A)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(A)</td><td style="width:99%">
a licensed board-eligible or board-certified psychiatrist;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(j)(ii)(B)" name="26-61a-104(2)(j)(ii)(B)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(B)</td><td style="width:99%">
a licensed psychologist with a master's-level degree;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(j)(ii)(C)" name="26-61a-104(2)(j)(ii)(C)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(C)</td><td style="width:99%">
a licensed clinical social worker with a master's-level degree; or</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(j)(ii)(D)" name="26-61a-104(2)(j)(ii)(D)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(D)</td><td style="width:99%">
a licensed advanced practice registered nurse who is qualified to practice within the psychiatric mental health nursing specialty and who has completed the clinical practice requirements in psychiatric mental health nursing, including in psychotherapy, in accordance with Subsection <a href="../../Title58/Chapter31B/58-31b-S302.html?v=C58-31b-S302_2022050420220504#58-31b-302(5)">58-31b-302(5)</a>(g);</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(k)" name="26-61a-104(2)(k)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(k)</td><td style="width:99%">
autism;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(l)" name="26-61a-104(2)(l)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(l)</td><td style="width:99%">
a terminal illness when the patient's remaining life expectancy is less than six months;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(m)" name="26-61a-104(2)(m)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(m)</td><td style="width:99%">
a condition resulting in the individual receiving hospice care;</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(n)" name="26-61a-104(2)(n)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(n)</td><td style="width:99%">
a rare condition or disease that:<a id="26-61a-104(2)(n)(i)" name="26-61a-104(2)(n)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
affects less than 200,000 individuals in the United States, as defined in Section 526 of the Federal Food, Drug, and Cosmetic Act; and</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(n)(ii)" name="26-61a-104(2)(n)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
is not adequately managed despite treatment attempts using:
<a id="26-61a-104(2)(n)(ii)(A)" name="26-61a-104(2)(n)(ii)(A)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(A)</td><td style="width:99%">
conventional medications other than opioids or opiates; or</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(n)(ii)(B)" name="26-61a-104(2)(n)(ii)(B)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(B)</td><td style="width:99%">
physical interventions;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(o)" name="26-61a-104(2)(o)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(o)</td><td style="width:99%">
pain lasting longer than two weeks that is not adequately managed, in the qualified medical provider's opinion, despite treatment attempts using:<a id="26-61a-104(2)(o)(i)" name="26-61a-104(2)(o)(i)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(i)</td><td style="width:99%">
conventional medications other than opioids or opiates; or</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(o)(ii)" name="26-61a-104(2)(o)(ii)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(ii)</td><td style="width:99%">
physical interventions;</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(p)" name="26-61a-104(2)(p)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(p)</td><td style="width:99%">
pain that is expected to last for two weeks or longer for an acute condition, including a surgical procedure, for which a medical professional may generally prescribe opioids for a limited duration, subject to Subsection <a href="../../Title26/Chapter61A/26-61a-S201.html?v=C26-61a-S201_2022032420220324#26-61a-201(5)(c)">26-61a-201(5)(c)</a>; and</td>
</tr>
</tbody></table>
<a id="26-61a-104(2)(q)" name="26-61a-104(2)(q)"></a>
<table width="100%">
<tbody><tr>
<td style="vertical-align:text-top">(q)</td><td style="width:99%">
a condition that the Compassionate Use Board approves under Section <a href="../../Title26/Chapter61A/26-61a-S105.html?v=C26-61a-S105_2022032420220324">26-61a-105</a>, on an individual, case-by-case basis.</td>
</tr>
</tbody></table>
</td>
</tr>
</tbody></table>
<br>
<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=277&amp;sess=2022GS">277</a>, 2022 General Session<br>Amended by Chapter <a href="http://le.utah.gov/UtahCode/ChapterLookup.jsp?chap=452&amp;sess=2022GS">452</a>, 2022 General Session<br>
</body></html>